UroDev Medical, Formerly Spinal Singularity, Announces New CEO and Minneapolis Headquarters

Feb. 2, 2021 13:00 UTC

Urology medtech veteran will lead development and commercialization of fully internal smart catheter for patients with chronic urinary retention

MINNEAPOLIS--(BUSINESS WIRE)-- UroDev Medical, formerly known as Spinal Singularity, Inc., a medical device company dedicated to delivering products that improve the lives of people suffering from chronic urinary retention, today announced that it has appointed seasoned medical device executive Matt Monarski as the company’s chief executive officer.

Monarski joins the company with nearly 30 years of global commercial experience focused on advancing new urology, gynecology and orthopedic medical device technologies. Prior to joining UroDev Medical, Monarski held senior leadership positions at NeoTract | Teleflex, where he built the brand, led high-performance teams, cultivated worldwide key opinion leader networks, and spearheaded product launches and market development opportunities to successfully drive adoption of the company’s UroLift® System. Prior to NeoTract | Teleflex, Matt held a variety of marketing, sales and product management roles, most recently at American Medical Systems and Tornier. He holds a BA and an MBA from the University of Saint Thomas.

The name UroDev Medical reflects the company’s mission, embodied by its IntelliFlow™ Bladder Management System (formerly the Connected Catheter System), to improve the lives of those who wear permanent indwelling urinary catheters or live with intermittent catheterizations due to urinary retention. The new company name also conveys the company’s evolution as it looks to broaden its device use beyond spinal injury patients.

The company also announced the relocation of its corporate headquarters from San Clemente, Calif. to Minneapolis, Minn.

“We have evolved significantly as a company and wanted to have a name that reflects this growth,” said Derek Herrera, founder and chief technology officer of UroDev Medical. “We believe the IntelliFlow System will not only help men suffering from urinary retention due to spinal injury, but all men experiencing the disruptive symptoms of this condition. I’m excited with the progress we’ve made as we approach our goal of bringing the product to the U.S. market. This is the perfect time to welcome Matt, a proven leader in bringing innovative solutions to the field of urology, as we prepare to become a commercial-stage company.”

“UroDev Medical is poised to successfully address a condition that affects millions of men in the U.S., and I couldn’t be more excited to join this team during this critical time in the company’s evolution,” said Monarski. “I believe in the potential of this disruptive technology to fill a growing clinical need in the urology space, and I look forward to leading the company through its next phase to submit for FDA clearance and prepare for commercialization.”

UroDev Medical has completed multiple clinical studies at sites across the U.S. and has initiated a pivotal clinical trial, the FREEDOM Study, to generate evidence in support of future regulatory submissions.

About UroDev Medical

UroDev Medical is an early stage, venture-backed medical device company developing the IntelliFlow™ Bladder Management System – the first extended-use, wirelessly controlled bladder management system for adult males with chronic urinary retention. IntelliFlow is fully internal to the body and may replace up to 50 disposable intermittent catheters. For more information please visit the company’s website at www.UroDevMedical.com.

CAUTION: The IntelliFlow™ Bladder Management System is currently an Investigational Device. Limited by Federal (United States) law to investigational use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005231/en/


Erica Smythe

Source: UroDev Medical

Back to news